Skip to content
Maimon Research LLC

  • Home
  • Distance Education Programs
  • Programs For Purchase
  • Working Papers
  • Questions and Answers
Latest Working Papers

WILL WE FINALLY ABANDON THE MATHEMATICALLY IMPOSSIBLE QALY WITH H.R. 485 PASSING IN THE SENATE?

March 8, 2024 Dr Paul Langely 472 Views

Paul C. Langley, Ph.D., Adjunct Professor, College of Pharmacy, University of Minnesota, Minneapolis, MN

The Maimon Working Papers are free to download (in PDF format) at the bottom of the page.
Maimon-WP-No.-3-March-2024-V5-2Download
  • REJECTING THE PBAC GUIDELINES FOR IMAGINARY COST-EFFECTIVENESS VALUE CLAIMS: A PROPOSED NEW START FOR HEALTH TECHNOLOGY ASSESSMENT IN AUSTRALIA
  • FALSE PREMISES AND IMAGINARY CLAIMS: THE PSEUDOSCIENCE OF THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE GUIDELINES

DIRECT LINKS

  • LATENT CONSTRUCTS
  • RASCH POSSESSION
  • RASCH NUMBER LINE
  • NUMERICAL STORYTELLING
  • OBJECTIVE KNOWLEDGE
  • LOGIT RATIO SCALE
  • IMPOSSIBLE QALY
  • IMPOSSIBLE REFERENCE CASE
  • VALUE CLAIMS
  • CHEERS 2022 GUIDELINE

Most Viewed Working Papers

  • CORE VALUE CLAIMS, PROTOCOLS AND FORMULARY EVALUATIONS
  • NOTHING TO CHEER ABOUT: ENDORSING IMAGINARY ECONOMIC EVALUATIONS
  • AN ORDINAL OVERSIGHT: ABANDONING THE TUFTS
  • FUNDAMENTAL MEASUREMENT AND THERAPY RESPONSE
  • VALUE CLAIMS AND THE NEW START IN RARE DISEASE
  • REJECTING PSEUDOSCIENCE: TEN COMMANDMENTS
  • EVIDENTIARY STANDARDS FOR PATIENT-CENTRIC CORE IMPACT
  • DAMAGED GOODS: IMAGINARY ICER VALUE ASSESSMENTS
  • MEASUREMENT AND RESPONSE TO THERAPY
Copyright © 2025 Maimon Research LLC. All rights reserved.
Privacy Policy